(19)
(11) EP 1 453 512 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
19.07.2006 Bulletin 2006/29

(45) Mention of the grant of the patent:
31.05.2006 Bulletin 2006/22

(21) Application number: 02792867.0

(22) Date of filing: 03.12.2002
(51) International Patent Classification (IPC): 
A61K 31/4709(2006.01)
A61P 25/00(2006.01)
C07D 405/06(2006.01)
C07D 209/08(2006.01)
C07C 271/16(2006.01)
C07C 271/24(2006.01)
 A61K 31/404(2006.01)
C07D 209/32(2006.01)
C07D 405/12(2006.01)
C07D 209/44(2006.01)
C07C 233/23(2006.01)
C07D 215/20(2006.01)
(86) International application number:
PCT/EP2002/013670
(87) International publication number:
WO 2003/047581 (12.06.2003 Gazette 2003/24)

(54)

ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY

ACETYLEN-DERIVATE MIT MGLUR 5 ANTAGONISTISCHER WIRKUNG

DERIVES D'ACETYLENE POSSEDANT UNE ACTIVITE ANTAGONISTE MGLUR 5

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR
Designated Extension States:
RO

(30) Priority: 04.12.2001 GB 0128996

(43) Date of publication of application:
08.09.2004 Bulletin 2004/37

(73) Proprietors:
  • Novartis AG
    4056 Basel (CH)
    Designated Contracting States:
    BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR 
  • Novartis Pharma GmbH
    1235 Wien (AT)
    Designated Contracting States:
    AT 

(72) Inventors:
  • GASPARINI, Fabrizio
    CH-4415 Lausen (CH)
  • AUBERSON, Yves
    CH-4123 Allschwil (CH)
  • OFNER, Silvio
    CH-4142 Münchenstein (CH)
  • Hart, Terance W.
    Cambridge CB3 0RS (GB)
  • Zimmermann, Kaspar
    4104 Oberwil BL (CH)


(56) References cited: : 
WO-A-02/46166
WO-A-02/062323
 WO-A-99/02497
US-A- 4 129 658
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).